Skip to main content
main-content

11-11-2020 | ACR 2020 | Conference coverage | Video

LILAC: BIIB059 improves active joint count in SLE

Richard Furie discusses the potential benefits of BIIB059, an antibody that blocks blood dendritic cell antigen 2, in the treatment of systemic lupus erythematosus and the science behind its phase 2 success (4:47).

Read transcript

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits